Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict whether cancer will come back after treatment.
PURPOSE: This laboratory study is identifying genes that may help predict recurrence in women with breast cancer treated with chemotherapy.
Genetic: microarray analysis
Genetic: protein expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
|Official Title:||Identifying Genomic Predictors of Recurrence After Adjuvant Chemotherapy|
- Distant, local/regional, and ipsilateral breast relapse [ Designated as safety issue: No ]
- First breast cancer recurrence [ Designated as safety issue: No ]
- Relapse-free interval [ Designated as safety issue: No ]
- Distant involvement at time of first recurrence [ Designated as safety issue: No ]
- Disease-free survival [ Designated as safety issue: No ]
- Overall survival [ Designated as safety issue: No ]
- Assess the prognostic utility of the Oncotype DX™ 21 gene profile for risk of relapse in women with node positive or high-risk node negative breast cancer.
- Identify individual genes whose RNA expression is associated with an increased risk of relapse in these patients.
- Perform an exploratory analysis of individual genes whose RNA expression is associated with an increased risk of relapse differentially in patients previously treated with docetaxel.
OUTLINE: This is a multicenter study.
Tissue samples are examined for association of RNA expression and clinical factors (e.g., tumor size, nodal status, hormone receptor status, age, menopause status), as well as estrogen receptor, progesterone receptor, and HER-2/neu expression by immunohistochemistry and other studies.
PROJECTED ACCRUAL: A total of 900 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00897299
|Study Chair:||Joseph A. Sparano, MD||Albert Einstein College of Medicine of Yeshiva University|
|OverallOfficial:||Lori J. Goldstein, MD||Fox Chase Cancer Center|